Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
39.80
+2.33 (6.22%)
At close: Oct 6, 2025, 4:00 PM EDT
40.00
+0.20 (0.50%)
After-hours: Oct 6, 2025, 7:58 PM EDT
Scholar Rock Holding Employees
Scholar Rock Holding had 128 employees as of December 31, 2024. The number of employees decreased by 22 or -14.67% compared to the previous year.
Employees
128
Change (1Y)
-22
Growth (1Y)
-14.67%
Revenue / Employee
n/a
Profits / Employee
-$2,466,305
Market Cap
3.83B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128 | -22 | -14.67% |
| Dec 31, 2023 | 150 | 36 | 31.58% |
| Dec 31, 2022 | 114 | -31 | -21.38% |
| Dec 31, 2021 | 145 | 26 | 21.85% |
| Dec 31, 2020 | 119 | 26 | 27.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SRRK News
- 13 days ago - Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions - Seeking Alpha
- 13 days ago - Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection - Benzinga
- 13 days ago - Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 13 days ago - US FDA declines to approve Scholar Rock's muscle weakness drug - Reuters
- 13 days ago - FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility - Business Wire
- 24 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment - Business Wire
- 2 months ago - Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript - Seeking Alpha